H5 Influenza Vaccines—Moving Forward Against Pandemic Threats
- 19 November 2024
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 332 (19) , 1609-1610
Abstract
This Viewpoint discusses H5 influenza vaccine use in light of the current outbreak and how vaccine development, stockpiling, and deployment could shape the US’ response to future pandemics.Keywords
This publication has 4 references indexed in Scilit:
- Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virusNature Medicine, 2024
- Pathogenicity and transmissibility of bovine H5N1 influenza virusNature, 2024
- Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody ResponsesClinical Infectious Diseases, 2023
- Investing in Immunity: Prepandemic Immunization to Combat Future Influenza PandemicsClinical Infectious Diseases, 2015